We are pleased to advise that deep linking capability, enabling users to directly download individual mobile toolkits, has now been released on the RDS mobile app. When you install the update, you will see that each toolkit has a small QR code icon the header area beside the search icon – see screenshot below. Clicking on this icon will open up a window with a full-size QR code and the alternative of a short URL for sharing with users. Instructions are provided.
You may need to actively install the update to install RDS app version 4.7.1 to see this improvement. Installing this update is also strongly recommended to get the full benefits of the new contingency arrangements – specifically, that if the RDS website should fail, you will still be able to download new mobile app toolkits.
To check your current RDS version, click on the three dots bottom right of the RDS app screen. This takes you to a “More” page where you will see the version number. To install latest updates:
On iPhones – go to the Apple store, click on your profile icon top right, scroll down to see the apps waiting to be updated and update the RDS app.
On Android phones – these can vary, but try going to the Google Play store, click on your profile icon top right, click on “Manage apps and device”, select and update the RDS app.
Please get in touch with ann.wales3@nhs.scot with any questions.
Long-acting depot injections are used for the patient’s convenience or to improve compliance. They may produce more extrapyramidal reactions than oral preparations. For traditional depot preparations (flupentixol, fluphenazine, haloperidol and zuclopenthixol decanoate) the BNF recommends giving a test dose as some side-effects are prolonged. The drug is dissolved in oil and, when injected into muscle, it slowly comes out of the oil and into the bloodstream over a period of up to 6 weeks. Peak levels are achieved within 10 days. Steady blood levels are achieved by 6 to 12 weeks, depending on which drug is used.
Solution for injection (oily) 20mg/mL, 40mg/2mL,100mg/mL, 200mg/mL
By deep intramuscular injection into the upper outer buttock or lateral thigh, test dose 20mg, then after at least 7 days 20 to 40mg repeated at intervals of 2 to 4 weeks, adjusted according to response; maximum 400mg weekly; usual maintenance dose 50mg every 4 weeks to 300mg every 2 weeks. Older people, initially quarter to half adult dose.
Solution for injection (oily) 50mg/mL, 100mg/mL
By deep intramuscular injection into the gluteal muscle, initially 50mg every 4 weeks, if necessary increasing by 50mg increments to 300mg every 4 weeks; higher doses may be needed in some patients. Older people, initially 12·5 to 25mg every 4 weeks.
Solution for injection (oily) (Clopixol®) 200mg/mL, 500mg/mL
By deep intramuscular injection into the upper outer buttock or lateral thigh, test dose 100mg, followed after at least 7 days by 200 to 500mg or more, repeated at intervals of 1 to 4 weeks, adjusted according to response; maximum 600mg weekly. Older people, quarter to half usual starting dose.
MHRA advice: Aripiprazole (Abilify and generic brands): risk of pathological gambling (December 2023) (www.gov.uk).
Powder and solvent for prolonged-release suspension for injection vial (Abilify Maintena®) 400mg, pre-filled syringe 400mg (s)
By deep intramuscular injection into the gluteal muscle, 400mg repeated at monthly intervals (minimum 26 days between injections). Continue treatment with 10 to 20mg of oral aripiprazole for 14 consecutive days after the first injection. For dose adjustments due to side- effects, concomitant use of interacting drugs or missed depot doses, consult SPC.
MHRA advice: Drug-name confusion: reminder to be vigilant for potential errors (January 2018) (www.gov.uk)
MHRA advice: Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery (December 2014) (www.gov.uk)
Powder and solvent for suspension for injection (Risperdal Consta®) 25mg, 37·5mg, 50mg
By deep intramuscular injection into the deltoid or gluteal muscle, patients taking oral risperidone up to 4mg daily, initially 25mg every 2 weeks; patients taking oral risperidone over 4mg daily, initially 37·5mg every 2 weeks; dose adjusted at intervals of at least 4 weeks in steps of 12·5mg to maximum 50mg (older people 25mg) every 2 weeks.
MHRA advice: Risperidone and paliperidone: risk of intraoperative floppy iris syndrome in patients undergoing cataract surgery (December 2014) (www.gov.uk)
Suspension for injection, pre-filled syringe (Xeplion®) 50mg, 75mg, 100mg, 150mg (s)
By deep intramuscular injection into the deltoid muscle, 150mg on day 1, then 100mg on day 8, then adjusted at monthly intervals according to response; recommended maintenance dose 75mg (range 25 to 150mg) monthly.
Prolonged-release suspension for injection, pre-filled syringe (Trevicta®) 175mg, 263mg, 350mg, 525mg (s)
By deep intramuscular injection into the deltoid muscle,
for 3-monthly maintenance treatment in patients who are clinically stable on 1-monthly paliperidone injection; refer to SPC.
As per SMC 1181/16: paliperidone palmitate (Trevicta®), a three-monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on one-monthly paliperidone palmitate injectable product.
TAM (Treatments and Medicines) NHS Highland